ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA International Myeloma Foundation 7:44 10 months ago 239 Далее Скачать
Updated Safety and Efficacy Results of Abbv-383 | Ravi Vij, MD, MBA | ASH 2023 HealthTree Foundation for Multiple Myeloma 3:22 11 months ago 147 Далее Скачать
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 1:14 1 year ago 112 Далее Скачать
How can the unique structure of the bispecific ABBV-383 impact its safety and efficacy? Multiple Myeloma Hub 4:57 1 year ago 293 Далее Скачать
Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with RRMM International Myeloma Foundation 6:43 5 months ago 250 Далее Скачать
Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:23 10 months ago 214 Далее Скачать
Insights into the Phase III CERVINO trial: ABBV-383 for R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 1:27 2 months ago 73 Далее Скачать
ABBV-383 - Upcoming Myeloma Treatment HealthTree University for Multiple Myeloma 19:49 1 year ago 973 Далее Скачать
Phase I study of ABBV383, a novel BCMAxCD3 bispecific antibody, in R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 2:50 2 years ago 50 Далее Скачать
First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMM International Myeloma Foundation 4:28 2 years ago 254 Далее Скачать
Phase I study of teclistamab, a humanized BCMA x CD3 bispecific antibody, in relapsed/refractory MM International Myeloma Foundation 3:44 4 years ago 703 Далее Скачать
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 1:29 4 years ago 87 Далее Скачать
Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:20 4 years ago 148 Далее Скачать
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results International Myeloma Foundation 9:57 3 years ago 1 156 Далее Скачать
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM International Myeloma Foundation 7:06 3 years ago 1 093 Далее Скачать
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 2:02 9 months ago 107 Далее Скачать
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:30 3 years ago 133 Далее Скачать
Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM International Myeloma Foundation 7:25 3 years ago 414 Далее Скачать
Teclistamab: BCMA x CD3 bispecific antibody in RRMM VJHemOnc – Video Journal of Hematology & HemOnc 3:41 4 years ago 800 Далее Скачать
REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 5:28 1 year ago 171 Далее Скачать
